Cargando…
CON: Serum biomarker monitoring should not replace primary antifungal chemoprophylaxis in patients with acute leukaemia receiving systemic anti-cancer therapy
Primary antifungal chemoprophylaxis (PAC) is the widespread strategy of choice for the prevention of invasive fungal disease in patients with acute leukaemia (AL). Twice-weekly monitoring of the serum biomarkers (SBM) galactomannan and 1,3-β-d-glucan has been proposed as an alternative prevention st...
Autores principales: | Howard, Alex, Hope, William |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305492/ https://www.ncbi.nlm.nih.gov/pubmed/35891676 http://dx.doi.org/10.1093/jacamr/dlac081 |
Ejemplares similares
-
Should serum biomarker monitoring replace primary antifungal chemoprophylaxis
in patients with acute leukaemia receiving systemic anti-cancer therapy? A PRO/CON
debate
por: Harrison, Thomas, et al.
Publicado: (2022) -
PRO: Biomarker surveillance for invasive fungal infections without antifungal
prophylaxis could safely reduce antifungal use in acute leukaemia
por: Taynton, Thomas, et al.
Publicado: (2022) -
An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP++
por: Mieras, Liesbeth F, et al.
Publicado: (2018) -
Why should HCWs receive priority access to vaccines in a pandemic?
por: Symons, Xavier, et al.
Publicado: (2021) -
Baseline testing in cluster randomised controlled trials: should this be done?
por: Bolzern, Jaime E., et al.
Publicado: (2019)